News | February 28, 2023
ENHERTU approved in China for patients with HER2 positive metastatic breast cancer treated withantiHER2-based regimens
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.
APAC to see a reduction in imported surgical robotics
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
One in two women with advanced ovarian cancer has an HRD-positive tumor
Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA
The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
The company was directed to submit a plan of compliance by July 15, 2022
Subscribe To Our Newsletter & Stay Updated
